Early SUSVIMO in Neovascular Age-Related Macular Degeneration: Real Word Case Report and Clinical Implications
Although effective, real-world management of neovascular age-related macular degeneration is associated with an extensive treatment burden that can compromise treatment adherence. Herein, we describe how the port delivery system (PDS; SUSVIMO) - a refillable ocular implant that can continuously deliver a novel formulation of ranibizumab with refills possible at six months or longer - is a viable early therapy that mitigates the treatment burden of intravitreal injections.
Authors
- Eric K. Chin (ORCID: https://orcid.org/0000-0003-2274-8194)
- David R.P. Almeida (ORCID: https://orcid.org/0000-0002-1742-1683)
- Jakob M Pericak (ORCID: https://orcid.org/0009-0002-7748-945X)
Institutions
- SUNY Geneseo (US)
- California Retina Consultants (US)
- Loma Linda Veterans Association for Research and Education (US)
- Erie VA Medical Center (US)
- VA Loma Linda Healthcare System (US)
Publication Details
- Journal
- International Medical Case Reports Journal
- Published
- 2024-10-01
- DOI
- https://doi.org/10.2147/imcrj.s475284
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Regeneron Pharmaceuticals